On November 18, Gronghui reported that Peijia Medical-B (09996.HK) announced that recently, the group's product TaurusTrioTM transcatheter aortic valve replacement ("TAVR") system for treating symptomatic severe aortic regurgitation ("AR") successfully completed the first compassionate use in Hong Kong.

By January 2024, the company has completed patient enrollment for the multicenter registration clinical trial of the TaurusTrioTM TAVR system conducted in China. Follow-up assessments for the subsequent stages are ongoing. The company expects to commercialize this product after obtaining regulatory approval in China to meet the unmet needs of a large number of AR patients.